Britannia Life Sciences Statistics

Total Valuation

Britannia Life Sciences has a market cap or net worth of CAD 12.98 million. The enterprise value is 24.13 million.

Market Cap	12.98M
Enterprise Value	24.13M

Important Dates

The next estimated earnings date is Thursday, February 27, 2025.

Earnings Date	Feb 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Britannia Life Sciences has 162.25 million shares outstanding. The number of shares has increased by 0.03% in one year.

Current Share Class	n/a
Shares Outstanding	162.25M
Shares Change (YoY)	+0.03%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	36.78%
Owned by Institutions (%)	0.93%
Float	102.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.79
PB Ratio	8.55
P/TBV Ratio	n/a
P/FCF Ratio	13.30
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.30
EV / Sales	3.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	24.73

Financial Position

The company has a current ratio of 0.25, with a Debt / Equity ratio of 1.20.

Current Ratio	0.25
Quick Ratio	0.23
Debt / Equity	1.20
Debt / EBITDA	6.00
Debt / FCF	7.62
Interest Coverage	0.91

Financial Efficiency

Return on equity (ROE) is -75.63% and return on invested capital (ROIC) is 4.08%.

Return on Equity (ROE)	-75.63%
Return on Assets (ROA)	2.93%
Return on Capital (ROIC)	4.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.31
Inventory Turnover	12.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.29% in the last 52 weeks. The beta is 0.46, so Britannia Life Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	+14.29%
50-Day Moving Average	0.05
200-Day Moving Average	0.06
Relative Strength Index (RSI)	62.81
Average Volume (20 Days)	13,058

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Britannia Life Sciences had revenue of CAD 7.26 million and -7.31 million in losses. Loss per share was -0.05.

Revenue	7.26M
Gross Profit	4.41M
Operating Income	1.09M
Pretax Income	-7.21M
Net Income	-7.31M
EBITDA	1.13M
EBIT	1.09M
Loss Per Share	-0.05

Full Income Statement

Balance Sheet

The company has 977,176 in cash and 7.43 million in debt, giving a net cash position of -6.45 million or -0.04 per share.

Cash & Cash Equivalents	977,176
Total Debt	7.43M
Net Cash	-6.45M
Net Cash Per Share	-0.04
Equity (Book Value)	6.22M
Book Value Per Share	0.01
Working Capital	-8.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 998,105 and capital expenditures -22,228, giving a free cash flow of 975,877.

Operating Cash Flow	998,105
Capital Expenditures	-22,228
Free Cash Flow	975,877
FCF Per Share	0.01

Full Cash Flow Statement

Margins

Gross margin is 60.71%, with operating and profit margins of 15.07% and -100.60%.

Gross Margin	60.71%
Operating Margin	15.07%
Pretax Margin	-99.28%
Profit Margin	-100.60%
EBITDA Margin	15.56%
EBIT Margin	15.07%
FCF Margin	13.44%

Dividends & Yields

Britannia Life Sciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.03%
Shareholder Yield	-0.03%
Earnings Yield	-56.29%
FCF Yield	7.52%

Stock Splits

The last stock split was on November 18, 2021. It was a reverse split with a ratio of 0.1.

Last Split Date	Nov 18, 2021
Split Type	Reverse
Split Ratio	0.1

Scores

Britannia Life Sciences has an Altman Z-Score of -0.76. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.76
Piotroski F-Score	n/a